China Medical GatewayLoading your healthcare gateway…

Colorectal Cancer in China

Overview

Colorectal cancer develops from adenomatous polyps in the colon or rectum over several years, which makes it one of the most preventable and, when detected early, most curable cancers. Screening colonoscopy is therefore central to care.

Chinese high-volume centers perform robotic and laparoscopic resections with enhanced-recovery protocols that shorten hospital stays, and offer transanal techniques that make sphincter-preserving surgery possible for low rectal tumors.

Symptoms & Signs

Change in bowel habit — diarrhea, constipation or narrower stools — lasting more than a few weeks

Rectal bleeding or blood mixed in the stool

Iron-deficiency anemia and unexplained fatigue

Abdominal discomfort, cramping or bloating

Unexplained weight loss in advanced disease

Polyps themselves are asymptomatic and removed during screening before becoming cancer

Diagnosis

Colonoscopy with biopsy — the definitive diagnostic test

CT of chest, abdomen and pelvis, with PET-CT for selected cases, for staging

Serum CEA tumor-marker measurement for prognosis and follow-up

MRI of the rectum defining tumor depth and margin for rectal cancer planning

MSI/MMR, RAS and BRAF molecular testing guiding targeted therapy

Treatment Options

Laparoscopic or robotic colectomy with complete mesenteric excision

Total mesorectal excision (TME) for rectal cancer, increasingly via transanal (TaTME) approach

Neoadjuvant chemoradiotherapy or total neoadjuvant therapy for locally advanced rectal cancer

Adjuvant chemotherapy for node-positive colon cancer

Targeted therapy (anti-EGFR, anti-VEGF) combined with chemotherapy for metastatic disease

Surgical or ablative treatment of liver and lung oligometastases for long-term control

Advanced Technologies & Novel Drug

da Vinci robotic rectal surgery with precise nerve-sparing dissection

3D laparoscopy and fluorescence (ICG) perfusion assessment of anastomoses

ERAS enhanced-recovery protocols shortening hospital stay

Circulating tumor DNA monitoring after surgery for early relapse detection

Novel immunotherapy for MSI-H tumors and targeted combinations for refractory disease

Hospital & Specialist

Return to Home